Blueprint Medicines Corp’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Haviland Kate unloaded Company’s shares for reported $0.23 million on Nov 29 ’24. In the deal valued at $96.60 per share,2,353 shares were sold. As a result of this transaction, Haviland Kate now holds 150,824 shares worth roughly $14.26 million.
Then, Rossi Christina sold 2,274 shares, generating $216,257 in total proceeds. Upon selling the shares at $95.10, the CHIEF OPERATING OFFICER now owns 71,657 shares.
Before that, KATHRYN D HAVILAND bought 3,799 shares. Blueprint Medicines Corp shares valued at $361,285 were divested by the Officer at a price of $95.10 per share.
JP Morgan initiated its Blueprint Medicines Corp [BPMC] rating to an Overweight in a research note published on November 14, 2024; the price target was $126. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Neutral”‘ rating. Stephens began covering BPMC with “an Overweight” recommendation on May 14, 2024. Leerink Partners revised its rating on May 06, 2024. It rated BPMC as “a Market perform” which previously was an “an Underperform”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -1.46% to $94.57. Over the last five days, the stock has lost -3.12%. Blueprint Medicines Corp shares have risen nearly 2.53% since the year began. Nevertheless, the stocks have risen 28.18% over the past one year. While a 52-week high of $121.90 was reached on 07/16/24, a 52-week low of $71.97 was recorded on 02/14/24. SMA at 50 days reached $91.61, while 200 days put it at $96.71.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 93.67, which if violated will result in even more drops to 92.78. On the upside, there is a resistance level at 96.23. A further resistance level may holdings at 97.90. The Relative Strength Index (RSI) on the 14-day chart is 50.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 41.18%. Stochastics %K at 67.34% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2024-11-15, growing by 0.29 million shares to a total of 3.91 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 3.62 million shares. There was a rise of 7.48%, which implies that there is a positive sentiment for the stock.
